Evaluation of Periodontitis and Fusobacterium nucleatum Among Colorectal Cancer Patients: An Observational Cross-Sectional Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Recruitment
2.2. Medical Anamnesis and Collection of Medical Records
2.3. Dental Examination: Orthopantomography (OPG) and Periodontal Charting
- Stage I: Initial periodontitis;
- Stage II: Moderate periodontitis;
- Stage III: Severe periodontitis with potential tooth loss;
- Stage IV: Advanced periodontitis with extensive tooth loss and potential outcome of edentulism.
2.4. F. nucleatum Assessment
2.4.1. Positive Control Strains
2.4.2. DNA Extraction
2.4.3. Real-Time Quantitative PCR
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Koliarakis, I.; Messaritakis, I.; Nikolouzakis, T.K.; Hamilos, G.; Souglakos, J.; Tsiaoussis, J. Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer. Int. J. Mol. Sci. 2019, 20, 4146. [Google Scholar] [CrossRef] [PubMed]
- Cheng, Y.; Ling, Z.; Li, L. The Intestinal Microbiota and Colorectal Cancer. Front. Immunol. 2020, 11, 615056. [Google Scholar] [CrossRef] [PubMed]
- Wang, N.; Fang, J.-Y. Fusobacterium nucleatum, a Key Pathogenic Factor and Microbial Biomarker for Colorectal Cancer. Trends Microbiol. 2023, 31, 159–172. [Google Scholar] [CrossRef]
- Zhou, Y.; Gao, H.; Mihindukulasuriya, K.A.; La Rosa, P.S.; Wylie, K.M.; Vishnivetskaya, T.; Podar, M.; Warner, B.; Tarr, P.I.; Nelson, D.E.; et al. Biogeography of the Ecosystems of the Healthy Human Body. Genome Biol. 2013, 14, R1. [Google Scholar] [CrossRef]
- De Luca, F.; Shoenfeld, Y. The Microbiome in Autoimmune Diseases. Clin. Exp. Immunol. 2019, 195, 74–85. [Google Scholar] [CrossRef]
- Arimatsu, K.; Yamada, H.; Miyazawa, H.; Minagawa, T.; Nakajima, M.; Ryder, M.I.; Gotoh, K.; Motooka, D.; Nakamura, S.; Iida, T.; et al. Oral Pathobiont Induces Systemic Inflammation and Metabolic Changes Associated with Alteration of Gut Microbiota. Sci. Rep. 2014, 4, 4828. [Google Scholar] [CrossRef]
- Laforgia, A.; Di Venere, D.; Capodiferro, S.; Granberg, V.G.; Barile, G.B.; Corsalini, M. Use of Lactobacillus Reuteri DSM 17938 in the Treatment of Stage II–III Periodontitis: Longitudinal Study of 36 Patients. J. Clin. Adv. Dent. 2024, 8, 1–8. [Google Scholar] [CrossRef]
- Fan, X.; Alekseyenko, A.V.; Wu, J.; Peters, B.A.; Jacobs, E.J.; Gapstur, S.M.; Purdue, M.P.; Abnet, C.C.; Stolzenberg-Solomon, R.; Miller, G.; et al. Human Oral Microbiome and Prospective Risk for Pancreatic Cancer: A Population-Based Nested Case-Control Study. Gut 2018, 67, 120–127. [Google Scholar] [CrossRef]
- Ahn, J.; Chen, C.Y.; Hayes, R.B. Oral Microbiome and Oral and Gastrointestinal Cancer Risk. Cancer Causes Control 2012, 23, 399–404. [Google Scholar] [CrossRef]
- Rubinstein, M.R.; Baik, J.E.; Lagana, S.M.; Han, R.P.; Raab, W.J.; Sahoo, D.; Dalerba, P.; Wang, T.C.; Han, Y.W. Fusobacterium nucleatum Promotes Colorectal Cancer by Inducing Wnt/Β-catenin Modulator Annexin A1. EMBO Rep. 2019, 20, e47638. [Google Scholar] [CrossRef] [PubMed]
- Flemer, B.; Lynch, D.B.; Brown, J.M.R.; Jeffery, I.B.; Ryan, F.J.; Claesson, M.J.; O’Riordain, M.; Shanahan, F.; O’Toole, P.W. Tumour-Associated and Non-Tumour-Associated Microbiota in Colorectal Cancer. Gut 2017, 66, 633–643. [Google Scholar] [CrossRef] [PubMed]
- Liang, Q.; Chiu, J.; Chen, Y.; Huang, Y.; Higashimori, A.; Fang, J.; Brim, H.; Ashktorab, H.; Ng, S.C.; Ng, S.S.M.; et al. Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer. Clin. Cancer Res. 2017, 23, 2061–2070. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.; Liu, Y.; Fan, W.; Fan, B. Fusobacterium nucleatum Triggers Proinflammatory Cell Death via Z-DNA Binding Protein 1 in Apical Periodontitis. Cell Commun. Signal. 2022, 20, 196. [Google Scholar] [CrossRef] [PubMed]
- Socransky, S.S.; Haffajee, A.D.; Cugini, M.A.; Smith, C.; Kent, R.L. Microbial Complexes in Subgingival Plaque. J. Clin. Periodontol. 1998, 25, 134–144. [Google Scholar] [CrossRef]
- Bui, F.Q.; Almeida-da-Silva, C.L.C.; Huynh, B.; Trinh, A.; Liu, J.; Woodward, J.; Asadi, H.; Ojcius, D.M. Association between Periodontal Pathogens and Systemic Disease. Biomed. J. 2019, 42, 27–35. [Google Scholar] [CrossRef]
- Antonacci, A.; Praino, E.; Abbinante, A.; Favia, G.; Rotondo, C.; Bartolomeo, N.; Giotta, M.; Iannone, F.; Orrù, G.; Agneta, M.T.; et al. Orofacial Manifestation of Systemic Sclerosis: A Cross-Sectional Study and Future Prospects of Oral Capillaroscopy. Diagnostics 2024, 14, 437. [Google Scholar] [CrossRef]
- Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via Its FadA Adhesin. Cell Host Microbe 2013, 14, 195–206. [Google Scholar] [CrossRef]
- Drewes, J.L.; Housseau, F.; Sears, C.L. Sporadic Colorectal Cancer: Microbial Contributors to Disease Prevention, Development and Therapy. Br. J. Cancer 2016, 115, 273–280. [Google Scholar] [CrossRef]
- TNM Classification of Malignant Tumours|UICC. Available online: https://www.uicc.org/what-we-do/sharing-knowledge/tnm (accessed on 4 June 2024).
- Tonetti, M.S.; Greenwell, H.; Kornman, K.S. Staging and Grading of Periodontitis: Framework and Proposal of a New Classification and Case Definition. J. Periodontol. 2018, 89 (Suppl. S1), S159–S172. [Google Scholar] [CrossRef]
- Momen-Heravi, F.; Babic, A.; Tworoger, S.S.; Zhang, L.; Wu, K.; Smith-Warner, S.A.; Ogino, S.; Chan, A.T.; Meyerhardt, J.; Giovannucci, E.; et al. Periodontal Disease, Tooth Loss and Colorectal Cancer Risk: Results from the Nurses’ Health Study. Int. J. Cancer 2017, 140, 646–652. [Google Scholar] [CrossRef] [PubMed]
- Fu, M.M.; Chien, W.; Chung, C.; Lee, W.; Tu, H.; Fu, E. Is Periodontitis a Risk Factor of Benign or Malignant Colorectal Tumor? A Population-Based Cohort Study. J. Periodontal Res. 2022, 57, 284–293. [Google Scholar] [CrossRef] [PubMed]
- Xuan, K.; Jha, A.R.; Zhao, T.; Uy, J.P.; Sun, C. Is Periodontal Disease Associated with Increased Risk of Colorectal Cancer? A Meta-Analysis. Int. J. Dent. Hyg. 2021, 19, 50–61. [Google Scholar] [CrossRef] [PubMed]
- Ren, H.G.; Luu, H.N.; Cai, H.; Xiang, Y.B.; Steinwandel, M.; Gao, Y.T.; Hargreaves, M.; Zheng, W.; Blot, W.J.; Long, J.R.; et al. Oral Health and Risk of Colorectal Cancer: Results from Three Cohort Studies and a Meta-Analysis. Ann. Oncol. 2016, 27, 1329–1336. [Google Scholar] [CrossRef] [PubMed]
- Kim, G.W.; Kim, Y.-S.; Lee, S.H.; Park, S.G.; Kim, D.H.; Cho, J.Y.; Hahm, K.B.; Hong, S.P.; Yoo, J.-H. Periodontitis Is Associated with an Increased Risk for Proximal Colorectal Neoplasms. Sci. Rep. 2019, 9, 7528. [Google Scholar] [CrossRef]
- Janati, A.I.; Karp, I.; Latulippe, J.-F.; Charlebois, P.; Emami, E. Periodontal Disease as a Risk Factor for Sporadic Colorectal Cancer: Results from COLDENT Study. Cancer Causes Control CCC 2022, 33, 463–472. [Google Scholar] [CrossRef]
- Hu, J.-M.; Shen, C.-J.; Chou, Y.-C.; Hung, C.-F.; Tian, Y.-F.; You, S.-L.; Chen, C.-Y.; Hsu, C.-H.; Hsiao, C.-W.; Lin, C.-Y.; et al. Risk of Colorectal Cancer in Patients with Periodontal Disease Severity: A Nationwide, Population-Based Cohort Study. Int. J. Colorectal Dis. 2018, 33, 349–352. [Google Scholar] [CrossRef]
- Mai, X.; LaMonte, M.J.; Hovey, K.M.; Freudenheim, J.L.; Andrews, C.A.; Genco, R.J.; Wactawski-Wende, J. Periodontal Disease Severity and Cancer Risk in Postmenopausal Women: The Buffalo OsteoPerio Study. Cancer Causes Control CCC 2016, 27, 217–228. [Google Scholar] [CrossRef]
- Michaud, D.S.; Lu, J.; Peacock-Villada, A.Y.; Barber, J.R.; Joshu, C.E.; Prizment, A.E.; Beck, J.D.; Offenbacher, S.; Platz, E.A. Periodontal Disease Assessed Using Clinical Dental Measurements and Cancer Risk in the ARIC Study. J. Natl. Cancer Inst. 2018, 110, 843–854. [Google Scholar] [CrossRef]
- Eke, P.I.; Page, R.C.; Wei, L.; Thornton-Evans, G.; Genco, R.J. Update of the Case Definitions for Population-Based Surveillance of Periodontitis. J. Periodontol. 2012, 83, 1449–1454. [Google Scholar] [CrossRef]
- Di Spirito, F.; Toti, P.; Pilone, V.; Carinci, F.; Lauritano, D.; Sbordone, L. The Association between Periodontitis and Human Colorectal Cancer: Genetic and Pathogenic Linkage. Life 2020, 10, 211. [Google Scholar] [CrossRef] [PubMed]
- Weinberg, B.A.; Hartley, M.L.; Salem, M.E. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor. Oncology 2017, 31, 539–548. [Google Scholar]
- Song, L.; Yao, J.; He, Z.; Xu, B. Genes Related to Inflammation and Bone Loss Process in Periodontitis Suggested by Bioinformatics Methods. BMC Oral Health 2015, 15, 105. [Google Scholar] [CrossRef] [PubMed]
- Kawamoto, D.; Amado, P.P.L.; Albuquerque-Souza, E.; Bueno, M.R.; Vale, G.C.; Saraiva, L.; Mayer, M.P.A. Chemokines and Cytokines Profile in Whole Saliva of Patients with Periodontitis. Cytokine 2020, 135, 155197. [Google Scholar] [CrossRef]
- Hanus, M.; Parada-Venegas, D.; Landskron, G.; Wielandt, A.M.; Hurtado, C.; Alvarez, K.; Hermoso, M.A.; López-Köstner, F.; De la Fuente, M. Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment. Front. Immunol. 2021, 12, 612826. [Google Scholar] [CrossRef]
- Kitamoto, S.; Nagao-Kitamoto, H.; Hein, R.; Schmidt, T.M.; Kamada, N. The Bacterial Connection between the Oral Cavity and the Gut Diseases. J. Dent. Res. 2020, 99, 1021–1029. [Google Scholar] [CrossRef] [PubMed]
- Geva-Zatorsky, N.; Sefik, E.; Kua, L.; Pasman, L.; Tan, T.G.; Ortiz-Lopez, A.; Yanortsang, T.B.; Yang, L.; Jupp, R.; Mathis, D.; et al. Mining the Human Gut Microbiota for Immunomodulatory Organisms. Cell 2017, 168, 928–943.e11. [Google Scholar] [CrossRef]
- Yuan, X.; Liu, Y.; Kong, J.; Gu, B.; Qi, Y.; Wang, X.; Sun, M.; Chen, P.; Sun, W.; Wang, H.; et al. Different Frequencies of Porphyromonas Gingivalis Infection in Cancers of the Upper Digestive Tract. Cancer Lett. 2017, 404, 1–7. [Google Scholar] [CrossRef]
- Flemer, B.; Warren, R.D.; Barrett, M.P.; Cisek, K.; Das, A.; Jeffery, I.B.; Hurley, E.; O’Riordain, M.; Shanahan, F.; O’Toole, P.W. The Oral Microbiota in Colorectal Cancer Is Distinctive and Predictive. Gut 2018, 67, 1454–1463. [Google Scholar] [CrossRef]
- Sears, C.L.; Garrett, W.S. Microbes, Microbiota, and Colon Cancer. Cell Host Microbe 2014, 15, 317–328. [Google Scholar] [CrossRef]
- Pignatelli, P.; Nuccio, F.; Piattelli, A.; Curia, M.C. The Role of Fusobacterium nucleatum in Oral and Colorectal Carcinogenesis. Microorganisms 2023, 11, 2358. [Google Scholar] [CrossRef] [PubMed]
- Peng, B.-J.; Cao, C.-Y.; Li, W.; Zhou, Y.-J.; Zhang, Y.; Nie, Y.-Q.; Cao, Y.-W.; Li, Y.-Y. Diagnostic Performance of Intestinal Fusobacterium nucleatum in Colorectal Cancer: A Meta-Analysis. Chin. Med. J. Engl. 2018, 131, 1349–1356. [Google Scholar] [CrossRef] [PubMed]
- Huangfu, S.-C.; Zhang, W.-B.; Zhang, H.-R.; Li, Y.; Zhang, Y.-R.; Nie, J.-L.; Chu, X.-D.; Chen, C.-S.; Jiang, H.-P.; Pan, J.-H. Clinicopathological and Prognostic Significance of Fusobacterium nucleatum Infection in Colorectal Cancer: A Meta-Analysis. J. Cancer 2021, 12, 1583–1591. [Google Scholar] [CrossRef] [PubMed]
- Eisele, Y.; Mallea, P.M.; Gigic, B.; Stephens, W.Z.; Warby, C.A.; Buhrke, K.; Lin, T.; Boehm, J.; Schrotz-King, P.; Hardikar, S.; et al. Fusobacterium nucleatum and Clinicopathologic Features of Colorectal Cancer: Results from the ColoCare Study. Clin. Colorectal Cancer 2021, 20, e165–e172. [Google Scholar] [CrossRef]
- Gao, R.; Kong, C.; Huang, L.; Li, H.; Qu, X.; Liu, Z.; Lan, P.; Wang, J.; Qin, H. Mucosa-Associated Microbiota Signature in Colorectal Cancer. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 2073–2083. [Google Scholar] [CrossRef]
Periodontitis | Stage I | Stage II | Stage III | Stage IV | |
---|---|---|---|---|---|
Severity | Interdental Clinical Attachment Level (at site of greatest loss) | 1–2 mm | 3–4 mm | ≥5 mm | ≥5 mm |
Radiographic Bone Loss | Coronal third (<15%) | Coronal third (15–33%) | Extending to the middle third of the root and beyond | Extending to middle third of the root and beyond | |
Tooth loss (due to periodontitis) | No tooth loss | ≤4 teeth | ≥5 teeth | ||
Complexity | Local |
|
| In addition to Stage II complexity, the following were ntoed:
| In addition to Stage III complexity, the following were noted:
|
Extent and distribution | Add to stage as descriptor | For each stage, describe extent as follows:
|
Oligo Sequence 5′------3′ | Oligo Name | GenBank Accession/Gene | |
---|---|---|---|
F. nucleatum | GGCCACAAGGGGACTGAGACA | OG41 | AJ133496/16 rRNA |
TTTAGCCGTCACTTCTTCTGTTGG | OG42 | ||
Total bacteria count | CCAGCAGCCGCGGTA | OG33 | 16S rRNA |
GACTACCRGGGTATCTAATC | OG123 |
Parameter | Stage CRC | |||||
---|---|---|---|---|---|---|
0–I (n = 13) | II (n = 22) | III (n = 20) | IV (n = 5) | p | ||
Periodontitis presence | 12 (92.3) | 21 (95.5) | 20 (100) | 5 (100) | 0.751 | |
Periodontitis stage | ||||||
Initial 1–2 | 2 (16.7) | 2 (9.5) | 5 (25.0) | 1 (20.0) | 0.539 | |
Severe 3–4 | 10 (83.3) | 19 (90.5) | 15 (75.0) | 4 (80.0) |
Periodontitis | Initial CRC (n = 35) | Advanced CRC (n = 25) | p | Overall CRC (n = 60) |
---|---|---|---|---|
Presence | 0.506 | |||
Yes | 33 (94.3%) | 25 (100%) | 58 (96.7%) | |
No | 2 (5.7%) | 0 (0%) | 2 (3.3%) | |
Stage | 0.302 | |||
Initial (Stage 1–2) | 4 (12.1%) | 6 (24.0%) | 10 (17.2%) | |
Severe (Stage 3–4) | 29 (87.9%) | 19 (76.0%) | 50 (82.8%) |
Parameter | n | % F. nucleatum (Mean ± SD) | p | |
---|---|---|---|---|
Sex | ||||
M | 34 | 16.9 ± 17.4 | 0.214 | |
F | 16 | 28.2 ± 24.2 | ||
Smoke | ||||
0 | 18 | 19.3 ± 19.6 | 0.374 | |
1 pack of cigarettes per day | 8 | 26.0 ± 19.6 | ||
2 pack of cigarettes per day | 23 | 18.3 ± 21.0 | ||
Cardiocirculatory diseases | ||||
Yes | 31 | 16.6 ± 17.8 | 0.166 | |
No | 19 | 27.0 ± 22.8 | ||
Diabetes | ||||
Yes | 9 | 10.5 ± 9.6 | 0.139 | |
No | 41 | 22.8 ± 21.4 | ||
Post-surgical complications | ||||
Yes | 20 | 19.0 ± 20.9 | 0.524 | |
No | 30 | 21.6 ± 20.1 | ||
CRC site | ||||
Right | 17 | 22.6 ± 23.1 | 0.195 | |
Left | 10 | 16.7 ± 12.6 | ||
Rectum | 20 | 17.5 ± 19.7 | ||
Transverse | 3 | 41.7 ± 22.8 | ||
CRC stage | ||||
0-I | 11 | 21.5 ± 23.0 | 0.827 | |
II | 14 | 16.8 ± 22.1 | ||
III | 14 | 17.9 ± 13.9 | ||
IV | 4 | 24.6 ± 21.7 | ||
ASA | ||||
1–2 | 25 | 24.0 ± 22.3 | 0.225 | |
3–4 | 24 | 15.7 ± 16.7 | ||
Periodontitis stage | ||||
1–2 | 8 | 31.2 ± 25.2 | 0.625 | |
3 | 19 | 19.9 ± 19.7 | ||
4 | 21 | 18.0 ± 19.3 |
Drug Category | n | % F. nucleatum (Mean ± SD) | p |
---|---|---|---|
Antiplatelets/anticoagulants | |||
yes | 19 | 15.8 ± 14.5 | 0.488 |
no | 30 | 22.3 ± 22.3 | |
Oral antidiabetics | |||
yes | 7 | 10.6 ± 9.6 | 0.217 |
no | 42 | 21.3 ± 20.6 | |
Antiarrhythmic antihypertensives | |||
yes | 24 | 15.0 ± 17.7 | 0.055 |
no | 25 | 24.4 ± 20.8 | |
Active on the Central Nervous System | |||
yes | 3 | 31.4 ± 34.0 | 0.358 |
no | 46 | 19.0 ± 18.8 | |
Diuretics | |||
yes | 4 | 11.0 ± 16.7 | 0.227 |
no | 45 | 20.6 ± 19.9 | |
Gastroprotective | |||
yes | 16 | 18.9 ± 15.1 | 0.715 |
no | 33 | 20.2 ± 21.8 | |
Insulin | |||
yes | 3 | 7.6 ± 6.5 | 0.284 |
no | 46 | 20.6 ± 20.1 | |
Prostatics | |||
yes | 12 | 27.5 ± 20.9 | 0.061 |
no | 37 | 17.3 ± 18.9 | |
Lipid-lowering | |||
yes | 17 | 16.4 ± 22.4 | 0.090 |
no | 32 | 21.6 ± 18.3 | |
Thyroid | |||
yes | 3 | 14.6 ± 18.5 | 0.572 |
no | 46 | 20.1 ± 19.9 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Antonacci, A.; Bizzoca, C.; Barile, G.; Andriola, V.; Vincenti, L.; Bartolomeo, N.; Abbinante, A.; Orrù, G.; Corsalini, M. Evaluation of Periodontitis and Fusobacterium nucleatum Among Colorectal Cancer Patients: An Observational Cross-Sectional Study. Healthcare 2024, 12, 2189. https://doi.org/10.3390/healthcare12212189
Antonacci A, Bizzoca C, Barile G, Andriola V, Vincenti L, Bartolomeo N, Abbinante A, Orrù G, Corsalini M. Evaluation of Periodontitis and Fusobacterium nucleatum Among Colorectal Cancer Patients: An Observational Cross-Sectional Study. Healthcare. 2024; 12(21):2189. https://doi.org/10.3390/healthcare12212189
Chicago/Turabian StyleAntonacci, Anna, Cinzia Bizzoca, Giuseppe Barile, Valeria Andriola, Leonardo Vincenti, Nicola Bartolomeo, Antonia Abbinante, Germano Orrù, and Massimo Corsalini. 2024. "Evaluation of Periodontitis and Fusobacterium nucleatum Among Colorectal Cancer Patients: An Observational Cross-Sectional Study" Healthcare 12, no. 21: 2189. https://doi.org/10.3390/healthcare12212189
APA StyleAntonacci, A., Bizzoca, C., Barile, G., Andriola, V., Vincenti, L., Bartolomeo, N., Abbinante, A., Orrù, G., & Corsalini, M. (2024). Evaluation of Periodontitis and Fusobacterium nucleatum Among Colorectal Cancer Patients: An Observational Cross-Sectional Study. Healthcare, 12(21), 2189. https://doi.org/10.3390/healthcare12212189